Rafael Holdings, Inc. - 8-K Filing
Rafael Holdings announces Phase 3 TransportNPC study results showing Trappsol® Cyclo™ did not achieve statistical significance but showed favorable treatment effect in NPC patients (Items: 7.01 Regulation FD On September 30, 2026, Rafael Holdings, Inc, 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”), 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $RFL